Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1800 participants
OBSERVATIONAL
2022-08-31
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units
NCT02551081
A Genome-Wide Association Study for Neonatal Diseases
NCT04074824
Utility of Rapid Whole Genome Sequencing in the NICU: A Pilot Study
NCT03918707
Assessment of Score System of Surgery in Necrotizing Enterocolitis(NEC) Patients
NCT04795453
Application of a Systematic Developmental Assessment to a Novel Population: Infants With Rare Genetic Disorders
NCT03967743
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Targeted sequencing, also known as next Generation sequence (NGS), has the advantages of fast sequencing, wide sequencing range, high sensitivity, high accuracy and low cost compared with traditional sequencing technology (Sanger sequencing). NGS has been widely used in tumor diseases, prenatal screening, drugs and the diagnosis of various genetic diseases. In prenatal screening, targeted sequencing is gradually used to detect free fetal DNA in pregnant women's peripheral blood, with an accuracy of 95%, which is much better than traditional amniocentesis karyotype analysis and improves the detection rate of secondary birth defects. Compared with traditional methods, NGS can provide diagnosis and classification, rich genetic disease gene spectrum, accurate direction for treatment, as well as the predict the risk of the next generation of children of the same disease. Therefore, targeted sequencing technology has great advantages for the diagnosis of children and prevention of newborn birth defect diseases.
To evaluate the efficacy of NGS in the screening and diagnosis of neonatal disease, the investigator lauched the "Budding Action". This study is to evaluate the application of NGS in the diagnosis of neonatal disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
conventional NBS+ infants
Disease diagnosis is carried out using conventional diagnosis and treatment methods.
No interventions assigned to this group
conventional NBS+ infants (NGS)
Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
NGS
In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
NICU infants
Disease diagnosis is carried out using conventional diagnosis and treatment methods.
No interventions assigned to this group
NICU infants (NGS)
Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
NGS
In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
Premature infants
Disease diagnosis is carried out using conventional diagnosis and treatment methods.
No interventions assigned to this group
Premature infants (NGS)
Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
NGS
In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NGS
In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* After fully understanding the program, the guardian signs the informed consent and agrees to participate in the program.
Exclusion Criteria
* Neonates have received transfusion of allogeneic blood products;
* Newborns whose guardians explicitly refuse to participate in the program after receiving the mission.
1 Day
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Hospital of Chongqing Medical University
OTHER
Xuzhou maternal and Child Health Care Hospital
UNKNOWN
Shanghai Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lin Zou
Role: PRINCIPAL_INVESTIGATOR
Shanghai Children's Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
shercru-20220003-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.